The companies mentioned see a broad commitment, not just for vaccine, but also at HIV, Tuberculosis, cancer and rare genetic diseases. It is not foreseeable which companies will ultimately succeed and win the race. Moderna and Biontech are currently safely at the top with their pipeline.
—
